Delivery Order SPE2DB22D3011-SPE2DB26FP7HR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100-count units) under a firm fixed-price contract valued at $2,646.20. The contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract. The award, issued on August 5, 2025, carries a ceiling value of $12,115.04 and requires completion by August 6, 2025. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count) with a ceiling value of $29,095.35. This firm fixed-price, non-set-aside contract is scheduled for completion by September 17, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100 count) with a ceiling value of $1,079.80. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 31, 2025. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units) with a ceiling value of $5,840.03. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical products...
- The Defense Logistics Agency awarded a delivery order contract valued at $2,586.18 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 70 mg capsules in quantities of 100 units. This competitive, non-set-aside award with firm fixed pricing was issued on October 24, 2025, with an ultimate completion date of October 27, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Lisdexamfetamine 50 mg capsules (90-count units) with a ceiling value of $8,109.38. This firm fixed-price delivery order, with an ultimate completion date of October 21, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 40 mg capsules (100 count) valued at $10,977.83. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, utilizes firm fixed pricing with no set-aside designation. Performance will be conducted from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 13, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units) with a ceiling value of $2,762.83. This is a firm fixed-price, non-set-aside delivery order that must be completed by May 14, 2025, with performance executed from the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $1,050.75. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The contract utilizes no set-aside...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB26FP7HRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 20 mg capsules (100-count) with a ceiling value of $5,176.58 under a firm fixed-price contract type. The award was made on October 30, 2025, with an ultimate completion date of October 31, 2025, and no set-aside designation was utilized. The pharmaceutical products will be delivered to the Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical federal medical procurement vendor for military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains in open competition. This delivery order for Lisdexamfetamine, a controlled-release amphetamine-based medication used primarily for attention deficit hyperactivity disorder (ADHD), supports the broader federal healthcare mission to maintain pharmaceutical supply chains for military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 10/30/25 |